Distributor inventory

Type 2 diabetes mellitus (as an adjunct to diet and exercise) to improve glycaemic control; may be used alone or in combination with other antidiabetic medicines as prescribed

Vildagliptin is a DPP-4 inhibitor that increases levels of incretin hormones (GLP-1 and GIP). This enhances glucose-dependent insulin release and reduces glucagon secretion, helping lower blood glucose with a low risk of hypoglycaemia when used without sulfonylureas/insulin.

Take by mouth exactly as prescribed, usually once daily (SR formulation). Swallow whole; do not crush or chew. Can be taken with or without food; take at the same time each day and monitor blood glucose as advised.

Headache,dizziness,nausea,diarrhoea,abdominal pain,flatulence,upper respiratory tract infection,back pain,skin rash

Not for type 1 diabetes or diabetic ketoacidosis. Use with caution in liver disease; periodic liver function tests may be advised—stop and seek medical help if jaundice, dark urine, or persistent nausea/vomiting occur. Use caution in moderate to severe renal impairment; dose adjustment/alternative may be needed. Rare risk of pancreatitis—seek urgent care for severe persistent abdominal pain (may radiate to back) with/without vomiting. Hypoglycaemia risk increases when combined with sulfonylureas or insulin. If allergic reactions (angioedema, rash) occur, discontinue and consult a doctor.

Insulin and sulfonylureas (increased hypoglycaemia risk),ACE inhibitors (may increase risk of angioedema),thiazide/loop diuretics and corticosteroids (may worsen glycaemic control),beta-blockers (may mask hypoglycaemia symptoms)

Store below 25°C in a dry place, protected from light and moisture. Keep out of reach of children.

Galvus 100 mg Tablet,Zomelis 100 mg Tablet,Jalra 100 mg Tablet,Vilda 100 mg Tablet,Vildaday 100 mg Tablet